20 Posts Not to Miss from ESMO Gynaecological Cancers Congress 2025
The 16th ESMO Gynaecological Cancers Congress 2025 was held in Florence, Italy, from June 19 to 21, uniting oncologists, researchers, and healthcare professionals from around the world to explore the latest advancements in the management of gynaecological malignancies. Organized by the European Society for Medical Oncology (ESMO), the event continues to serve as a premier platform for science, clinical updates, and multidisciplinary exchange.
This year’s congress delivered a comprehensive and clinically driven program that bridged science and practice. From breakthrough data in ovarian, endometrial, and cervical cancers to discussions on molecular diagnostics, maintenance strategies, and immunotherapy, the sessions reflected the rapidly evolving treatment landscape. Highlights included state-of-the-art lectures, expert debates, multidisciplinary tumor boards, and sessions dedicated to precision medicine and patient advocacy.
With hundreds of abstracts presented and a robust turnout from across Europe and beyond, ESMO Gynaecological Cancers 2025 emphasized collaboration, innovation, and education. Special sessions focused on young oncologists and early-career professionals, underlining ESMO’s commitment to shaping the next generation of leaders in the field.
Now a key fixture in the oncology calendar, the 2025 edition reaffirmed ESMO’s mission to advance standards of care and foster high-impact research in gynaecological oncology. As treatment paradigms continue to shift, the congress offered a vital space to exchange ideas, forge new partnerships, and stay at the forefront of patient-centered cancer care.
Our team at OncoDaily has handpicked 20 highlights from ESMO Gynaecological Cancers Congress 2025. Scroll down to catch the highlights, dive into the science, and hear directly from the people shaping the future of cancer care.
“Challenging ageism in Gynaecologic Cancer. In an Opinion piece in the ESMO Daily Reporter, Elene Mariamidze discusses presentations at ESMOGynae25 that highlight suboptimal treatment of older women despite effective treatments irrespective of age. https://ow.ly/7iXC50WeikX .”
” What a fantastic ESMOGynae25! High-level scientific content, superb faculty, great networking opportunities, lovely moments with my mentors and friends.See you in Copenhagen! ESMO, Stephanie Lheureux, Ainhoa Madariaga, Luisa Bonilla. ”
“An analysis presented at ESMOGynae25 highlighted distinct patterns of expression of different antibody–drug conjugate (#ADC) targets in high-grade serous Ovarian Cancer samples. Further details in the ESMO Daily Reporter https://ow.ly/nFsm50WceVQ.”
“Young Oncologists at ESMOGynae25 with amazing Ainhoa Madariaga.”
“Rob Coleman summarizing whack a mole for PROC ESMOGynae25 .”
“This year marks my 16th ESMOGyn, and I’m truly excited to reconnect with colleagues, delve into groundbreaking GynecologicOncology research, and contribute to the vital Oncology Education shaping our field. As always, the chance to be in Vienna is a treat in itself—no trip is complete without a classic Wiener Schnitzel and a crisp pint of Maerzen. Looking forward to another impactful ESMOGyn2025 meeting as we come together to drive progress for patients and strengthen our global Oncology Community.”
“Highlights from day 1 ESMOGYNAE2025.”
- CtDNA in LGSOC could detect about 44% of KRAS mutations – an area for further improvement/development
- Novel combinations in rare cancers show promising data- SERD + CDK4/6 in low grade serous continues to show promise
- Another promising combo: oral cyclophosphamide/ Bev / pembro in LGSOC and clear cell
- Rosella trial- phase 3 Relacorilant showing promising data in PROC
” Encouraging results of the Piccolo trial with mirve in PSOC with median OS 21.17 months and ORR 51.9%!! ESMOGynae25.”
“ESMOGynae25: An analysis of the BEATcc trial revealed similar survival benefits with atezolizumab plus chemotherapy and bevacizumab regardless of PD-L1 status in untreated recurrent/metastatic Cervical Cancer. Read more in the ESMO Daily Reporter https://ow.ly/9pHG50Wcfbn.”
“Increased incidence of Cataract surgery in mirve studies. 42.3% vs 11.5% in unexposed to mirve. Odds 12 times more. More exposure = more cataracts. Why? Is it an AE, more ocular examen or may be due to prophyl ocular steroids? Don’t miss mini oral session in ESMOGynae25.”
“Back from an inspiring ESMOGynae25. Fantastic opportunity to learn from faculty & Network. Honoured to receive the Best Poster award Hospital Universitario 12 de Octubre & share an ADC session with Philip Harter & Christian Marth.”
“Truly proud to share our work at ESMOgynae25 this weekend: “Bevacizumab (Bev) in Platinum-Resistant Ovarian Cancer: Does prior exposure to Bev affect outcomes?” Grateful for the passion and dedication of our fellow Dr. Calvo. More data coming soon… GynOnc, Oncología Médica Hospital Ramón y Cajal.”
“ESMOGynae25: Relacorilant plus nab-paclitaxel resulted in significantly prolonged PFS and clinically meaningful OS improvements in the ROSELLA Clinical Trial in platinum-resistant Ovarian Cancer. More in the ESMO Daily Reporter https://ow.ly/Nbv650WcfvU.”
“Great presentation of Dr Ana Oaknin of Vall d’Hebron Institute of Oncology (VHIO) in ESMOGynae25 about ADC in endometrial cancer. Excellent talk !!!”
“Honored to present our study evaluating MIRV exposure increasing the incidence of cataract surgery in patients with ovarian cancer, cataract surgery in 60% of pts on MIRV >6 Mts,
etiology likely multifactorial: MIRV, ocular steroids, more frequent eye exams ESMOGynae25.”
“Excited to share that I presented a poster at ESMOGynae25! Sharing our work on implementation of PPI in the LYSA Trial. Huge thanks to my co-authors, and the ESMOGynae25 for the support.”
“Dr. Antonio Gonzalez Martin set perfectly the stage for treatment evolution in HRP patients. Very limited benefit from current CT and maintenance therapy options. Are we ready to explore non chemotherapy regimens for HRP pts? ESMOGyn25 ”
“ESMOGynae25: Findings from the PICCOLO trial confirmed the efficacy of mirvetuximab soravtansine-gynx in heavily pretreated patients with FRα-positive platinum-sensitive Ovarian Cancer regardless of HRD status. Read more in the ESMO Daily Reporter https://ow.ly/ZH7J50WcHC1.”
“Very interesting educational session in endometrial cancer in ESMOGynae25 we have learned a lot!!”
“Research presented at ESMOGynae25 evaluated the expression of five ADC targets to assess their potential applicability in Ovarian Cancer. Findings reveal targetable alterations, that could lead to better therapeutic options and improved patient outcomes.”
To stay on top of everything happening at ESMO Gynaecological Cancers Congress 2025, keep following OncoDaily.
Written by Nare Hovhannisyan, MD
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023